Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma

被引:52
作者
Fukahori, Suguru [1 ,2 ]
Yano, Hirohisa [1 ,3 ]
Tsuneoka, Makoto [3 ]
Tanaka, Yoshiaki [1 ,2 ]
Yagi, Minoru [2 ]
Kuwano, Michihiko [3 ]
Tajiri, Tatsuro [4 ]
Taguchi, Tomoaki [4 ]
Tsuneyoshi, Masazumi [5 ]
Kojiro, Masarnichi [1 ,3 ]
机构
[1] Kurume Univ, Sch Med, Dept Pathol, Fukuoka 8300011, Japan
[2] Kurume Univ, Sch Med, Dept Pediat Surg, Fukuoka 8300011, Japan
[3] Kurume Univ, 21st Century COE Program Med Sci, Res Ctr Innovat Canc Therapy, Fukuoka 8300011, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Pediat Surg, Fukuoka 8128582, Japan
[5] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 8128582, Japan
关键词
neuroblastoma; Cap43; Mina53; MYCN; TrkA; immunohistochemistry;
D O I
10.1016/j.jpedsurg.2007.07.008
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: We studied the expressions of both Mina53, which is a myc target gene and is related to cell proliferation, and Cap43, which is related to metastasis Suppression and downregulation of MYCN gene, in neuroblastoma. Methods: Forty-eight surgically obtained neuroblastoma specimens were immunohistochemically stained. The Cap43 and Mina53 expression levels were determined, and their relationship to clinical prognostic factors, biological prognostic factors, and the patients' prognosis were examined. Results: The Cap43 expression score was significantly high in the cases that had one of the good prognostic factors (<1 year old, early stage, mass screening case, no MYCN gene amplification), whereas the Mina53 expression score was high in those with poor prognostic factors. Regarding the MYCN expression site, the Cap43 expression score was significantly high in the cases demonstrating cytoplasm expression, whereas the Mina53 expression score was significantly high in the cases demonstrating nucleus expression. A significant relationship was found between Cap43 and TrkA, between Mina53 and Ki-67, and between Mina53 and TrkA. The prognosis was significantly favorable in the Cap43 high-expression cases, whereas it was significantly poor in the Mina53 high-expression cases. Conclusions: Cap43 and Mina53 are both considered to be important biological and prognostic factors in neuroblastoma. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1831 / 1840
页数:10
相关论文
共 44 条
[1]   Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines [J].
Ambros, PF ;
Ambros, IM .
MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 37 (06) :492-504
[2]  
Bandyopadhyay S, 2003, CANCER RES, V63, P1731
[3]  
BORDOW SB, 1994, CANCER RES, V54, P5036
[4]   AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE [J].
BRODEUR, GM ;
SEEGER, RC ;
SCHWAB, M ;
VARMUS, HE ;
BISHOP, JM .
SCIENCE, 1984, 224 (4653) :1121-1124
[5]   REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[6]   Biology and genetics of human neuroblastomas [J].
Brodeur, GM ;
Maris, JM ;
Yamashiro, DJ ;
Hogarty, MD ;
White, PS .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (02) :93-101
[7]  
BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111
[8]   Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma [J].
Caron, H ;
vanSluis, P ;
deKraker, J ;
Bokkerink, J ;
Egeler, M ;
Laureys, G ;
Slater, R ;
Westerveld, A ;
Voute, PA ;
Versteeg, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (04) :225-230
[9]  
Chan HSL, 1997, CLIN CANCER RES, V3, P1699
[10]   MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN [J].
Cohn, SL ;
London, WB ;
Huang, DH ;
Katzenstein, HM ;
Salwen, HR ;
Reinhart, T ;
Madafiglio, J ;
Marshall, GM ;
Norris, MD ;
Haber, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) :3604-3613